These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35415613)

  • 1. Inappropriate Empiric Therapy Impacts Complications and Hospital Resource Utilization Differentially Among Different Types of Bacterial Nosocomial Pneumonia: A Cohort Study, United States, 2014-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Zilberberg NWD; Shorr AF
    Crit Care Explor; 2022 Apr; 4(4):e0667. PubMed ID: 35415613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Dillon RJ; Shorr AF
    BMC Infect Dis; 2022 Oct; 22(1):775. PubMed ID: 36199012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Shorr AF
    Infect Control Hosp Epidemiol; 2022 Mar; 43(3):277-283. PubMed ID: 35322770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Machine learning to identify risk factors associated with the development of ventilated hospital-acquired pneumonia and mortality: implications for antibiotic therapy selection.
    Sophonsri A; Lou M; Ny P; Minejima E; Nieberg P; Wong-Beringer A
    Front Med (Lausanne); 2023; 10():1268488. PubMed ID: 38170135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial.
    Lodise T; Yang J; Puzniak LA; Dillon R; Kollef M
    Infect Dis Ther; 2020 Dec; 9(4):953-966. PubMed ID: 32996064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Descriptive epidemiology of hospitalized patients with bacterial nosocomial pneumonia who experience 30-day readmission in the US, 2014-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Zilberberg NWD; Shorr AF
    PLoS One; 2022; 17(12):e0276192. PubMed ID: 36490261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Descriptive Epidemiology and Outcomes of Nonventilated Hospital-Acquired, Ventilated Hospital-Acquired, and Ventilator-Associated Bacterial Pneumonia in the United States, 2012-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Shorr AF
    Crit Care Med; 2022 Mar; 50(3):460-468. PubMed ID: 34534129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
    Timsit JF; Huntington JA; Wunderink RG; Shime N; Kollef MH; Kivistik Ü; Nováček M; Réa-Neto Á; Martin-Loeches I; Yu B; Jensen EH; Butterton JR; Wolf DJ; Rhee EG; Bruno CJ
    Crit Care; 2021 Aug; 25(1):290. PubMed ID: 34380538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Naik J; Puzniak L; Critchlow S; Elsea D; Dillon RJ; Yang J
    Infect Dis Ther; 2021 Jun; 10(2):939-954. PubMed ID: 33837518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    Antimicrob Resist Infect Control; 2017; 6():124. PubMed ID: 29225798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
    Kollef MH; Timsit JF; Martin-Loeches I; Wunderink RG; Huntington JA; Jensen EH; Yu B; Bruno CJ
    Crit Care; 2022 Dec; 26(1):373. PubMed ID: 36457059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    Crit Care; 2016 Jul; 20(1):221. PubMed ID: 27417949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
    Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
    J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
    Martin-Loeches I; Shorr AF; Wunderink RG; Kollef MH; Timsit JF; Yu B; Huntington JA; Jensen E; Bruno CJ
    Ann Intensive Care; 2023 Feb; 13(1):8. PubMed ID: 36773112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Trials.
    Bart SM; Rubin D; Kim P; Farley JJ; Nambiar S
    Clin Infect Dis; 2021 Aug; 73(3):e602-e608. PubMed ID: 33173946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).
    Huntington JA; Yu B; Li L; Jensen E; Bruno C; Boakye M; Zhang Z; Gao W; Feng HP; Rhee E
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.
    Stergiopoulos S; Calvert SB; Brown CA; Awatin J; Tenaerts P; Holland TL; DiMasi JA; Getz KA
    Clin Infect Dis; 2018 Jan; 66(1):72-80. PubMed ID: 29020279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study.
    Zilberberg MD; Nathanson BH; Sulham K; Shorr AF
    BMC Infect Dis; 2021 Feb; 21(1):159. PubMed ID: 33557769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.